Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
Authors:
- 10 December 2009
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (35) , 5868-5873
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” DecisionJournal of Clinical Oncology, 2003
- Improving the evaluation of new cancer treatments: challenges and opportunitiesNature Reviews Cancer, 2003
- Lung Cancer — Time to Move on from ChemotherapyNew England Journal of Medicine, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001